Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Investment analysts at Seaport Res Ptn reduced their Q4 2024 earnings per share estimates for shares of Curaleaf in a note issued to investors on Sunday, November 17th. Seaport Res Ptn analyst S. Randhawa now anticipates that the company will post earnings of ($0.08) per share for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Seaport Res Ptn also issued estimates for Curaleaf's Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.21) EPS.
CURLF has been the topic of several other reports. Needham & Company LLC reaffirmed a "buy" rating and set a $6.25 price target on shares of Curaleaf in a research report on Thursday, August 8th. Cormark cut Curaleaf from a "moderate buy" rating to a "hold" rating in a research report on Thursday, November 7th. Finally, Roth Capital upgraded shares of Curaleaf to a "strong-buy" rating in a research note on Sunday, November 10th.
Read Our Latest Stock Report on Curaleaf
Curaleaf Stock Performance
OTCMKTS CURLF traded down $0.09 during trading hours on Wednesday, reaching $2.08. The stock had a trading volume of 741,652 shares, compared to its average volume of 714,959. Curaleaf has a 52-week low of $1.64 and a 52-week high of $6.40. The stock has a fifty day moving average of $2.85 and a 200 day moving average of $3.62. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11. The stock has a market cap of $1.35 billion, a P/E ratio of -7.16 and a beta of 0.86.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
